Research and Markets has announced the addition of the "Nicotine Addiction - Pipeline Review, H2 2016" drug pipelines to their offering.
Nicotine Addiction pipeline therapeutics constitutes close to 19 molecules. Out of which approximately 13 molecules are developed by Companies and remaining by the Universities/Institutes. Nicotine Addiction - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Nicotine Addiction Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT). The molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.
Key Topics Covered:
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/hx9cld/nicotine
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006228/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.